Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

BACKGROUND: We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy. METHODS: All patients with HR-positive metastatic breast cancer treated with siroli...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Zongbi, Liu, Binliang, Sun, Xiaoying, Rong, Guohua, Wang, Wenna, Li, Hui, Guan, Xiuwen, Li, Lixi, Zhai, Jingtong, Li, Chunxiao, Qian, Haili, Ma, Fei, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375615/
https://www.ncbi.nlm.nih.gov/pubmed/32335491
http://dx.doi.org/10.1016/j.breast.2020.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375615/
https://www.ncbi.nlm.nih.gov/pubmed/32335491
http://dx.doi.org/10.1016/j.breast.2020.04.004

Ejemplares similares